Rollover equity in a treatment center sale means keeping part of your economic exposure invested after closing. The important questions start with what you will own, who controls it, and how money could eventually reach you. A buyer’s projection can make the investment look attractive while leaving those questions unanswered. Before agreeing to roll proceeds, evaluate the proposed ownership as carefully as you evaluate the sale of your addiction treatment business.
Ask the buyer to draw the ownership structure and identify your exact investment. You might retain an interest in the existing provider, receive ownership in a holding company, or invest in a larger platform. Those arrangements expose you to different assets, liabilities, management decisions, and financing. A percentage without an identified entity and security class is incomplete. Obtain the governing documents and current capitalization table rather than relying on an offer summary.
This article focuses on the continuing investment. For the broader choice between liquidity and continued ownership, read addiction treatment growth capital, recapitalization, and full-sale alternatives. An earnout is a separate contingent-payment arrangement; its terms deserve their own review. Neither structure should be treated as cash available at closing.
A useful proposal identifies both the amount invested and the rights purchased. Ask for consistent answers across the letter of intent, funds flow, subscription documents, and operating or shareholder agreement. Resolve differences before the transaction becomes difficult to unwind. Your transaction counsel, tax advisor, and personal financial advisor should examine the arrangement from their respective perspectives.
For illustration only, suppose an owner is entitled to $5 million before taxes and chooses to invest $1 million in the buyer’s parent company. That is 20% of those proceeds. It does not establish 20% ownership of the parent. The ownership percentage depends on the negotiated investment valuation, capitalization, and security terms. Have the buyer show the exact calculation and reconcile it to the closing documents.
The following questions help convert a promising presentation into an investment you can understand. They are diligence prompts, not a recommendation to accept or reject a particular security. The answers must come from the actual documents and financial evidence. A familiar brand or a positive relationship with the acquisition team cannot substitute for them.
Ask whether your purchase price and security class match those of the sponsor or other investors. If they differ, identify why and model the effect. A common-share valuation may conceal a preferred class entitled to receive money first. Also ask whether transaction fees, acquisition debt, management incentives, or other closing adjustments alter the value immediately after your investment. “Same valuation” needs a definition that survives the complete capitalization table.
A platform may raise capital, acquire more providers, or expand its management incentive pool. Each can change your percentage or economic position. Request a simple example showing your ownership before and after an additional financing. Ask whether you have participation rights, whether exercising them requires more cash, and whether new securities can rank ahead of yours. Participation rights are only useful if their timing and funding requirements are practical for you.
Review the financing at the entity where you invest and its important subsidiaries. Ask about maturities, interest burden, lender restrictions, guarantees, and the assumptions used to service debt. Revenue growth does not automatically create distributable cash. In a downside case, staffing costs, reimbursement pressure, and financing obligations may absorb resources before owners receive anything. Request a bridge from operating results to debt service, required reinvestment, and potential distributions.
Specify which financial statements you receive, their frequency, and the deadline for delivery. Ask about budgets, annual reporting, material litigation, compliance findings, acquisitions, and capital raises. If a board seat is offered, understand its scope and the duties it may involve. If you have only consent rights, list the covered decisions. An informal promise to keep you involved can be difficult to use when management changes or a disagreement arises.
Your clinical or management role may end before the investment does. Review repurchase rights triggered by retirement, resignation, termination, disability, death, or an alleged breach. Ask how the repurchase price is determined, when it is paid, and whether you can challenge the calculation. A treatment-center founder planning to reduce hours should examine these provisions early. Compensation for future work and consideration for the business should remain clear, separate parts of the discussion.
Ask who can approve a sale, refinancing, distribution, or transfer of your interest. Examine drag-along, tag-along, transfer restrictions, and any proposed redemption right with counsel. None should be assumed to provide a guaranteed buyer or payment date. The SEC’s private-placement investor bulletin explains that applicable private securities can be illiquid, offer limited disclosure, and involve loss risk. Counsel should determine the rules and restrictions affecting your particular rollover.
Suppose a future transaction leaves $12 million of equity proceeds after debt and transaction costs. Assume, purely for illustration, that a senior class receives the first $4 million and your class shares the remaining $8 million. A 10% interest in that residual pool would produce $800,000, rather than 10% of the full $12 million. Real waterfalls may be more complicated, including participation rights and accrued preferences. Have advisors model your actual documents at several outcomes instead of treating this simplified example as a forecast.
You already know your clinical operation. The rollover may expose you to other locations, service lines, acquisition plans, and management teams. Review service mix, payer concentration, collections, staffing capacity, compliance processes, and integration performance across the relevant business. Ask what happens if acquired locations need more investment than expected. Your analysis should distinguish current earnings from planned improvements. Also examine how clinical concerns are escalated and whether management’s growth plan has the operating capacity to support appropriate care.
Resolve the commercial framework while negotiating the treatment-center letter of intent. Some documents will follow later, but material investment terms should not remain an undefined appendix to the cash offer.
Request the following before treating the proposed equity as an understood part of your proceeds. Where final documents are unavailable, identify the missing terms and who must resolve them. A short list of open issues is more useful than a large folder without clear answers.
Discuss unresolved items together rather than negotiating each document in isolation. A favorable valuation can be offset by restrictive repurchase terms. Strong information rights do not eliminate operating risk. The goal is a coherent arrangement whose uncertainties you understand, including the possibility that the investment may decline substantially or have no available liquidity.
Before deciding how much to roll, have your personal advisors assess taxes, debt repayment, near-term spending, and the resources you intend to keep available. Model those needs using cash you can actually access, with contingent payments and equity considered separately. Stress-test a period with no distributions and no exit. This does not determine the right rollover amount for every owner; it identifies how dependent your personal plans would be on an investment controlled partly by others.
Read the equity proposal alongside cash at closing, earnout payment conditions, escrows, working-capital adjustments, and your continuing duties. Avoid counting a dollar invested as a dollar of immediately available cash. If offers use different forms of consideration, ask your team to show each one on a consistent basis before you choose a preferred buyer.
Write down the investment terms you understand, those still open, and the risks your personal plan can absorb. Olympic M&A’s behavioral-health advisory work helps owners connect these questions to a broader sale process. Request a confidential conversation about your proposed transaction, then involve your legal, tax, and financial advisors in the specific investment review.
Tony Siebel is the Founder and Managing Director of Olympic M&A. His background includes corporate development and physician-practice acquisitions at MDVIP, as well as serving as Vice President and Associate Partner at Stoneridge Partners, including work in its Behavioral Health Division.
Olympic M&A advises founders and healthcare business owners on transactions with private equity groups and strategic acquirers. Learn more about the firm’s behavioral health advisory services and discuss the scope of support appropriate for your business.
Contact Olympic M&A | info@olympicma.com | 502.360.8320